Trial Profile
A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Nebivolol/Rosuvastatin combination treatment in patients with concomitant Hypertension and Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2020
Price :
$35
*
At a glance
- Drugs Nebivolol/rosuvastatin (Primary) ; Nebivolol; Rosuvastatin
- Indications Hyperlipidaemia; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Elyson Pharm
- 14 Jan 2020 Status changed from recruiting to completed.
- 16 Feb 2017 New trial record